



PRODUCT LEAFLET FOR DOCTORS & HUMAN PATIENTS

Please read this leaflet carefully

CVTherapy is only available as a “special” with a prescription from a doctor or pharmacy or from CV Pharma Limited. It should not be passed on to others.

Presentation.

CVTherapy: one capsule contains Manganese gluconate 10mg, Copper gluconate 10mg, Ascorbic Acid (Vitamin C) 200mg, Sodium Salicylate 175mg. They are supplied in bottles of 60 capsules. The individual constituents of CVTherapy are well characterised and used in other human medicines or supplements. All constituents are of pharmacopoeial specification.

What you should know about CVTherapy.

CVTherapy is a palliative treatment for cancer that is formulated to treat cancer which has been created by a deficiency of certain naturally occurring substances in the body. By replacing these substances, CVTherapy may bring about an improvement in the quality of life and potentially prevent the reoccurrence of tumours, and has minimal adverse side effects. It is non-toxic.

CVTherapy is patented as CV247 by Ivy Medical Chemicals Development Limited, a wholly-owned subsidiary of CV Pharma Ltd, under Patent Number: GB2374008B.

Mechanism of Action

Manganese and Copper are essential trace elements for the functioning of enzymes (such as Superoxide Dismutase, SOD) promoting the stimulation of the immune system and antioxidation processes. In malignant neoplasia these enzymes are not functioning adequately and thus cannot prevent the damages of DNA, a frequent cause of tumour formation.

Ascorbic Acid (Vitamin C) reduces the free radicals and other harmful oxidation products in the body and stimulates the immune system. It promotes the repair processes, the regeneration of connective tissue and wound healing.

Sodium Salicylate supports the anti-inflammatory processes and the reduction of pain thereby improving the quality of life of sick animals. It reduces oxidation processes by suppressing oxidizing enzymes (such as cyclooxygenase, COX-2) whose excessive activity enhances DNA damaging and the proliferation of tumour cells and their blood supply. It restores the correct balance between cell proliferation and natural cell-death (apoptosis).

Benefits of CVTherapy.

- Strengthens the immune system which provides improved Quality of Life
- Forms part of the body's anti-oxidant defences
- May prevent the reoccurrence of tumours
- May aid recovery from surgery, chemotherapy or radiotherapy
- May be taken adjunctively with chemotherapy and radiotherapy.

Before you use CVTherapy.

CVTherapy has been available for a significant number of years, and has proved to have minimal adverse side effects. However, as with all medicines, CVTherapy could potentially have minor side effects. Experiences from studies have demonstrated that adverse side effects are occasionally reported, predominantly relating to mild gastro-intestinal events such as gastric irritation, abdominal pain and bloating. No serious or severe reactions have ever been reported. CVTherapy should **not** be prescribed if the patient may be allergic to any of the ingredients, or suffer from hepatobiliary disease and should **not** be prescribed to pregnant patients. Salicylates should only be co-administered with anti-coagulant drugs with caution.

CV247 /CVTherapy Studies and Clinical Trials.

CV247Therapy has been the subject of a number of pre-clinical studies undertaken to ascertain the anti-tumour properties of CV247Therapy:

- A study in mice undertaken by Prof P Beverley at the Middlesex Hospital demonstrated a measurable reduction in the rate of tumour growth
- A study undertaken in mice by Biodynamics Ltd, which demonstrated tumour reduction was more apparent following treatment using CVTherapy rather than alternative substances.
- A chronic toxicology study was undertaken at Huntingdon Life Sciences, providing evidence that CVTherapy in

dogs has a very low side effect profile, with no reports of either severe or serious adverse effects attributable to the drug, even when administered in double therapeutic doses for 6 months.

- A study undertaken by Prof R Thomas at Addenbrooke's and Bedford Hospital evaluated the tumour static properties of CVTherapy, which wholly supported the clinical benefit in some types of cancer.
- A second study by Prof R Thomas, which resulted in a significant percentage of prostate cancer patients, who were recruited into the study, being stabilised following the treatment.
- A study undertaken by Dr Ros Taylor of the St Francis Hospice in Berkhamstead in order to ascertain how CVTherapy influenced quality of life found positive results in some patients with late stage cancers.
- A retrospective assessment conducted by Dr Ros Taylor over 5 years demonstrated significant symptom improvement or disease stabilisation in many patients.
- A multicentre veterinary clinical trial in Hungary resulted in the acceptance of its final Report for Registration of CVTherapy for cancer treatment of dogs as a paramedical substance with therapeutic effect in Hungary and several other EU countries.
- A preliminary viability investigation study undertaken by RGCC Limited (Research Genetic Cancer Centre) found that, after CVTherapy was added to a range of human cancer cell lines, it had a direct anti-cancer activity particularly in breast and colon cancers and considerably enhanced the cytotoxic effect if co-administered with cisplatin.
- A study in rats undertaken at Semmelweis University in Budapest found that CVTherapy reduced the oxidative effects and prevented the cisplatin induced renal damage when co-administered with it.

Dosage and administration.

CVTherapy should only be taken as prescribed. The dose prescribed will depend upon the patient's weight. CVTherapy should be taken orally with water.

The usual dose for adults and adolescents (13 years or more) is:

| Bodyweight | CVTherapy daily dosage |
|------------------------|-------------------------------|
| Under 50 Kg | Two capsules a day |
| 50 - 75 Kg | Four capsules a day |
| 75 Kg and above | Six capsules a day |

If you forget to take CVTherapy.

Do not worry; simply leave out that dose completely and then take your next dose at the right time. Do not try to make up for the missed dose.

Pharmaceutical precautions.

Keep CVTherapy out of reach and sight of children. Do not store above 25°C and store in the original package to protect the capsules from light.

How to obtain CVTherapy.

CVTherapy is only available as a "special" with a prescription from a doctor or pharmacy, or from CV Pharma Ltd.

Further Information & Enquiries

Further information is available from CV Pharma Limited, High Leybourne, Hascombe Road, Surrey GU8 4AD, United Kingdom; tel 0044 (0)7778 213337; Email: roger.wood@cvpharma.co.uk or from our website www.cv247therapy.com and review sections headed Documents & Downloads and Press & Media; or our password-protected website www.cv-pharma.com using username: **cvpharma247** and password: **cvpharma247** where we draw your attention to the section headed Useful Information containing videos, testimonials, and press articles.

Manufacturer

Nutrition Group Plc, Olympic Way, Blackpool FY4 4QE, United Kingdom

CVTherapy Product Leaflet for Doctors & Human Patients 9 January 2024.